SCHEMBL7605853

SCHEMBL7605853

FC1(F)c2cc(Br)ccc2-c2ccc(Br)cc2C1(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.48
AKR1A1 P14550 1/20 0.42
AKR1B1 P15121 1/20 0.42
S100A4 P26447 1/20 0.41
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
TDP2 O95551 1/20 0.38
PTPRC P08575 1/20 0.35
METAP1 P53582 1/20 0.35
BCL2 P10415 2/20 0.34
MCL1 Q07820 1/20 0.34
CYP2A6 P11509 2/20 0.33
TGM2 P21980 1/20 0.33
CES1 P23141 1/20 0.33
KDM1A O60341 1/20 0.33
AHR P35869 2/20 0.32
CMA1 P23946 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28235336 0.89 PDK2 (0.59) PDK2AKR1A1AKR1B1S100A4TDP2
SCHEMBL29540403 0.85 PDK2 (0.48) PDK2AKR1A1AKR1B1S100A4CA1
SCHEMBL206283 0.85 PDK2 (0.48) PDK2AKR1A1AKR1B1S100A4CA1
SCHEMBL13231061 0.81 PDK2 (0.46) PDK2AKR1A1AKR1B1S100A4CA1
SCHEMBL16891327 0.80 PDK2 (0.49) PDK2AKR1A1AKR1B1S100A4CA1
SCHEMBL29404184 0.79 PDK2 (0.47) PDK2AKR1A1AKR1B1S100A4CA1
SCHEMBL437007 0.79 PDK2 (0.47) PDK2AKR1A1AKR1B1S100A4CA1
SCHEMBL18129375 0.79 GSK3B (0.53) PDK2ALDH1A1
SCHEMBL7637916 0.79 ALDH1A1 (0.41) PDK2AKR1A1AKR1B1ALOX15ALDH1A1
SCHEMBL9266595 0.77 PDK2 (0.46) PDK2AKR1A1AKR1B1S100A4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512108-B2 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2016-12-06 US disclosed
US-9512108-B2 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2016-12-06 US disclosed
US-9512108-B2 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2016-12-06 US disclosed
EP-3091010-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2016-11-09 EP disclosed
EP-3091010-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2016-11-09 EP disclosed
US-20160297804-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2016-10-13 US disclosed
US-20160297804-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2016-10-13 US disclosed
US-20160297804-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2016-10-13 US disclosed
WO-2015101215-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF 南京圣和药业股份有限公司 2015-07-09 WO disclosed
EP-0837851-B1 FLUORINATED PHENANTHRENE DERIVATIVES AND THEIR USE IN LIQUID CRYSTAL MIXTURES AVENTIS RES & TECH GMBH & CO (DE) 2002-05-29 EP disclosed
US-5888422-A Fluorinated phenanthrene derivatives and their use in liquid-crystal mixtures HOECHST AKTIENGESELLSCHAFT (DE) 1999-03-30 US disclosed
EP-0837851-A1 FLUORINATED PHENANTHRENE DERIVATIVES AND THEIR USE IN LIQUID CRYSTAL MIXTURES HOECHST AKTIENGESELLSCHAFT (DE) 1998-04-29 EP disclosed
WO-1997002247-A1 FLUORINATED PHENANTHRENE DERIVATIVES AND THEIR USE IN LIQUID CRYSTAL MIXTURES HOECHST AKTIENGESELLSCHAFT (DE) 1997-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297804-A1 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF SLC10A1, CYP2C9, UGT1A9 PDK2 3770/4885AKR1A1 756/4885AKR1B1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.